The safety and efficacy of Firesorb bioresorbable scaffold in first-in-man study for coronary artery disease: the four-year outcomes.
10.3760/cma.j.cn112148-20201110-00897
- Author:
Chong Jian LI
1
;
Bo XU
2
;
Lei SONG
1
;
Meng Yue YU
1
;
Hong Bing YAN
1
;
Hong QIU
1
;
Chao Wei MU
1
;
Jin Gang CUI
1
;
Chang Dong GUAN
2
;
Zhong Wei SUN
2
;
Shu Bin QIAO
1
;
Run Lin GAO
1
Author Information
1. Department of Cardiology, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
2. Catheter Lab, Fuwai Hospital, National Cardiovascular Center, Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100037, China.
- Publication Type:Randomized Controlled Trial
- MeSH:
Absorbable Implants;
Cardiovascular Agents;
Coronary Artery Disease/surgery*;
Drug-Eluting Stents;
Humans;
Male;
Middle Aged;
Percutaneous Coronary Intervention;
Prospective Studies;
Sirolimus;
Treatment Outcome
- From:
Chinese Journal of Cardiology
2021;49(2):128-135
- CountryChina
- Language:Chinese
-
Abstract:
Objective: To evaluate the 4-year clinical outcomes of patients following Firesorb bioresorbable scaffold (BRS) implantation. Methods: The study reported the 4-year follow-up results of the FUTURE I study. FUTURE I was a prospective, single-center, open-label, first-in-man study which evaluated the feasibility, preliminary safety, and efficacy of Firesorb stent in the treatment of coronary artery stenosis. A total of 45 patients with single de novo lesions in native coronary arteries ,who hospitalized in Fuwai Hospital from January to March 2016 were enrolled. After successfully stent implantation these patients were randomized in a 2∶1 ratio into cohort 1 (n=30) or cohort 2 (n=15). The patients in cohort 1 underwent angiographic, IVUS or OCT examination at 6 months and 2 years; and cohort 2 underwent angiographic, IVUS or OCT at 1 and 3 years. All patients underwent clinical follow-up at 1, 6 months and 1 year and annually thereafter up to 5 years. The primary endpoint was target lesion failure (TLF, including cardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization). Secondary endpoints included patient-oriented composite endpoint (PoCE, defined as composite of all death, all miocardial infarction, or any revascularization). Results: A total of 45 patients were enrolled and implanted with Firesorb BRS, including 35 males (77.8%), and the age was (54.4±9.3) years. At 4 years, 10 patients in cohort 1 were reexamined by coronary angiography and OCT examination. Among them, 2 patients' stents were completely degraded and absorbed. Compared with the OCT images of the other 8 patients in cohort 2 at 3 years, the degree of stent degradation was increased, and no stent adherence was found. The 4-year clinical follow-up rate was 100%. In 4-year clinical following up, 2 patients suffered PoCE (4.4%): 1 patient underwent non-target vessel revascularization the day after index procedure and target vessel revascularization (Non-target lesion revascularization) at 2-year imaging follow-up; the other patient underwent target lesion revascularization during imaging follow-up at 4 years but not due to ischemic driven. There was no scaffold thrombosis or TLF events through 4 years. Conclusions: Four years after the implantation, complete degradation and absorption of the Firsorb stent are evidenced in some patients. Firesorb stent is feasible and effective in the treatment of patients with non-complex coronary lesions.
